10/07/2014

NEARLY 4,500 PEOPLE HAVE BENEFITED FROM ESTEVE’S SOCIAL AND WELFARE INITIATIVES

According to data published in its 2013 Sustainability Report

Barcelona, 11th July 2014. ESTEVE's 2013 Sustainability Report has again received an "A+" rating, thus becoming the only pharmaceutical company in Spain to earn this consideration for the seventh consecutive year. The "A+" rating is awarded by the Global Reporting Initiative (GRI), an international independent body that leads and supports the provision of transparent, verifiable information by companies on their own activities. This rating also implies that ESTEVE's 2013 Report contains the maximum number of GRI-established indicators, and that these values have been certified by an external company.

Aid to the most deprived
ESTEVE carries out different welfare initiatives, both in developing countries and in the most vulnerable populations of our country. Thus, in 2013, 4,490 people in total benefited from ESTEVE's collaboration with 23 non-profit organizations such as food banks and Cáritas, among others.
ESTEVE also adheres to the ten principles of the Global Compact and the Millennium Development Goals established by the United Nations. In this context, the company has set up a new model of medicine donations to hospitals, dispensaries, mother and child centres, accommodation facilities for sick people, orphanages and nursing homes in developing countries. In total, 37 expeditions to 21 different countries through 33 NGOs were carried out in 2013.
ESTEVE also participates in Farmamundi's Humanitarian and Emergency Aid Fund (FAHE), which in 2013 benefited 96,168 people through 10 interventions in 8 countries around the globe. These included emergency interventions in Kenya, Syria and the Philippines; post-emergency interventions in Mali and the Dominican Republic; and humanitarian aid in Palestine, the Democratic Republic of the Congo, and Uganda.

Environmental care
In 2013, industrial expenses and investments made according to efficiency criteria in different centres, as well as different public awareness campaigns, have allowed reducing CO2 emissions by 15%, that is, by 4,159 tons.
ESTEVE has also compensated for 375 tons of CO2 by means of a reforestation project in Chiapas (Mexico), where ESTEVE has a chemical plant. This project has been promoted by ECODES in the framework of the Zero CO2 Challenge, which also provides other environmental (preservation of biodiversity) and social (cooperation to the development of the most vulnerable populations) benefits.

Learn more at: ESTEVE Sustainability Report 2013

Last news

  • ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE

    Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europe

    read more
  • POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN

    The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugs

    read more
  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.